Argen X SE ADR (ARGX) is overvalued and Vertex Pharmaceuticals Inc (VRTX) is overvalued.
Both trade above our estimate of their intrinsic value. ARGX is the closer of the two: -27%, against -36% for VRTX.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 8.0% (average of 3 methods) values the shares at $758.94; the price of $963.79 is 27% above that value, and 81% of that value comes from beyond year five.
Leak Score 59/100 on 3 of 12 signals
Discounting its cash flows at 7.4% (average of 3 methods) values the shares at $380.05; the price of $514.99 is 36% above that value, and 82% of that value comes from beyond year five.
Leak Score 65/100 on 9 of 12 signals
| Metric | ARGX | VRTX |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Price | $963.79 | $514.99 |
| Intrinsic value | $758.94 | $380.05 |
| Margin of safety | -27% | -36% |
| Leak Score | 59/100 (3/12) | 65/100 (9/12) |
| Market cap | $60.3B | $130.5B |
| Revenue growth, 5 years | 151.4% | 14.2% |
| Operating margin | 28.8% | 39.5% |
| Net margin | 32.8% | 34.7% |
| Return on equity | 23.6% | 23.5% |
| Debt to equity | 0.01 | 0.10 |
| P/E | 36.7x | 30.0x |
| Forward P/E | 25.1x | 24.4x |
| P/B | 7.1x | 6.4x |